To improve selectivity, an EGFR-targeting cetuximab-based ADC loaded with a selective CDK2/7/9 inhibitor, SNS-032, was recently developed and reported to inhibit tumor growth in EGFR-high TNBC xenografts [209]. Here, EGFR is linked to neoplasm.